AbbVie would gain an experimental eczema drug by buying biotech: report

—·4h

AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.

ChannelsstocksCountriesusaCategoriespharma

Open original source ↗

Published

6/20/2026, 4:11:00 PM

Fetched

6/20/2026, 6:07:04 PM

Confidence

60 / 100

Relevance

37 / 100

Trust

—

Language